SEPSIS DIAGNOSTICS MARKET
“SEPSIS DIAGNOSTICS. Global Markets by Assay, by Cause, by Product, by Lab, and by Place. With Executive and Consultant Guides. 2023 - 2027”
397 Pages packed with information.
Rapid Results Drive Race for a Sepsis Diagnostic..…
Sepsis is affecting over 45 million people a year with no definitive diagnostic in hand. The race is on using all the genomic and molecular diagnostic tools that have come to the fore in the last decade. It is not clear who will be the winner, but the stakes are global and large. Emergency life saving diagnostics can command a premium in the market. Understand the different drivers of this huge global diagnostic market and find where the opportunities lie.
Our facts and support = Your success.
The report forecasts the market size out for five years. Growth is coming from the basic factors related to improving levels of health care throughout the world. In addition the legacy of the pandemic has changed the playing field for respiratory infections. Some players have already made their mark but disruptive diagnostic technology could change the playing field. Learn about this market including the issues and outlooks. The two key trends of Rapid Diagnostics and the Genomics Revolution are merging to create new diagnostic opportunities.
Our research makes you the expert in your organization. Get our research team working for you by ordering this comprehensive report. Your credit card order sends the report to your inbox instantly. Check all your licensing options but don't worry, your order is available as a credit if you wish to upgrade to a wider license. We wrote this report and we are ready, by phone or email, to help you use it. As always, assistance, and additional specific data, is provided without additional charges.
All report data is available in Excel format on request.
View the Table of Contents.
Send an email to us at email@example.com and we will happily email you a FREE copy of SAMPLE PAGES FROM THIS REPORT without any obligation on your part.
Make investment decisions and valuations with confidence using the latest data.
ABOUT THE LEAD AUTHOR
Mr. Greg Powell, B.SC., M.B.A is the President of Howe Sound Research.
He is an experienced business and clinical professional. He is co-author of the paper "The Radioimmunoassay of Angiotensinogen by Antibody Trapping." He has worked in laboratory testing and management for over 20 years. Mr. Powell’s education includes:
B.Sc. (Chemistry) University of BC
M.B.A. (Finance and Policy) University of BC
Market Research - Burke Institute
Finance for Senior Executives - Harvard Business School
Share this item: